Zyversa Therapeutics Highlights published the study that decides the strengthening of microglia-controlled inflammation in the development of Parkinson's and Alzheimer's diseases

• Study results confirm our recently published data that show the critical role of microglial inflammation in the promotion of accumulation and the spread of toxic phosphorylated alpha-synuclein, which leads to a neurodegenization in Parkinson's disease (PD).

• Our data showed that the microglia inflammation was driven by activating NLRP1 inflammosomes, which were triggered by ASC spots and alpha-synuclein aggregate. The inflammasom-asc-inhibitor IC 100 inhibited the NLRP1 inflammation activation, which reduced the mirrors and the spread of toxic phosphorylated alpha-synuclein.

• Our study was financed by a scholarship between Michael J. Fox Foundation and carried out by leading neurologists and inflammosome experts at the University of Miami School of Medicine.
  

Weston, Florida, May 20, 2025 (Globe Newswire) -Cyversa Therapeutics, Inc. (Nasdaq: ZVSA or “Zyversa”), a special stage of the clinical stage specialties of Biopharmazia, which for the first time develops the first classes for the treatment of inflammatory and renal diseases. Treatment for PD. There is an enormous medical need for therapeutic options that slow the progression of PD when it comes to over 10 million people worldwide. Current therapies that deal with symptoms but not the underlying disease pathology generated 6.6 billion US dollars worldwide in 2024 and are expected to generate $ 13.3 billion by 2034 (priority research).

This study was published in Experimental and Molecular Medicine, a journal of Nature examined by experts, and showed that microglial inflammation to spread phosphorylated α-synuclein and Tau proteins were expanded, which lead to the neurodegenerations and the development and progression of Parkinson's and Alzheimer's diseases.

“We are very pleased to see a second study that underpins the critical need to control the microglia inflammation in order to weaken the development and progression of Parkinson's disease,” said Stephen C. Glover, co-founder, chairman, CEO and President of Zyversa. “Our latest data showed that IC 100 the microglia inflammation by inhibiting the NLRP1 inflammosom activation and improving the clearance of toxic phosphorylated alpha-synuclein. In contrast to NLRP3 inhibitors, IC 100-blocks ASC, ASC, and several types of Inflames.

Study highlights

• Microglia cells, which were stimulated from neural cells by alpha-synuclein or dew, switched from homeostatic to an activated inflammatory condition.

• The transplantation of the inflammatory microglia into the striatum naive mice led to abnormal accumulation of alpha-synuclein or dew, severe gliosis (scars) and neuroinflammation.

• The above -mentioned pathological changes over the injection site existing.

• The mice experienced progressive motor and cognitive deficits.

The authors came to the conclusion: “These results finally show that microglic inflammation can trigger the entire area of ​​pathological characteristics observed in neurodegenerative diseases.”

Via inflammasom -Sc -inhibitor IC 100

IC 100 is a new, humanized monoclonal IGG4 antibody that inhibits the inflammasome adapter protein -Sc. IC 100 was developed to weaken both the inauguration and the maintenance of the inflammatory reaction. This is done by binding to a certain region of the ASC component of several types of inflammasomes, including NLRP1, NLRP2, NLRP3, NLRC4, AIM2 and Pyrin. Intracellularly binds IC 100 to ASC monomers and inhibits the formation of inflammation at the beginning of the inflammatory cascade. IC 100 also binds to ASC in ASC spots, both intracellularly and extracellular, which means that activation of IL-1 & BGR; And the continuation of the inflammatory reaction, which is pathogenic in inflammatory diseases, continues to block. Since active cytokines amplify adaptive immunity through various mechanisms, IC 100 also dampens adaptive immune response by weakening cytokin activation. The main display for IC 100 is obesity for certain metabolic complications. Click here to check a white paper in which the action mechanism and preclinical data for IC 100 are summarized.

Via Zyversa Therapeutics, Inc.

Zyversa (Nasdaq: ZVSA) is a biopharmaceutical company in the clinical stage that uses advanced proprietary technologies to develop first -class medication for patients with inflammatory or kidney diseases with high medical needs. We are well positioned in the fast -emerging inflammatory room with a highly differentiated monoclonal antibody, an inflammatory ASC inhibitor IC 100 and in kidney diseases with phase -2 -cholesterol -fflux mediator well positioned^TM VAR 200. The leading ad for IC 100 is obesity and the associated metabolic complications as well as for Var 200, focal segmental glomerulosclerosis (FSGS). Each therapeutic area offers a “pipeline within a product” with potentially numerous indications. The entire accessible market is over 100 billion US dollars. For more information, see www.zyversa.com.

Warning statement on forward -looking statements

Certain statements contained in this press release in relation to matters that are not historical facts are future -oriented statements within the meaning of Section 21e of the Securities Excurities Exchange Act from 1934 in the changed version, and the private law on the reform of the securities from 1995. deviate. Zyversa Therapeutics, Inc (“Zyversa) uses words like” anticipative “,” belief “,” plans “,” expected “,” projects “,” future “,” intend “,” may “,” will “,” should “,” “estimates”, “predict”, “predict”, “potentials”, “potentials”. Provisions for Safe-Harbbor. Such future -oriented statements are based on the expectations of cyversa and contain risks and uncertainties. As a result, the actual results can deviate and commercialize its product candidates due to a number of factors, including Zyversa's plans, from the statements expressed or implied in the statements, and the time of initiating the planned preclinical and clinical studies from Zyversa; the time of the availability of data from the preclinical and clinical studies of Zyversa; the time of a planned investigation of new drug application or new drug application; Cyversa's plans to research, develop and commercialize its current and future product candidates; clinical benefits, the potential advantages and the market acceptance of product candidates from Zyversa; The commercialization, marketing and manufacturing functions and strategy of Zyversa; Cyversa's ability to protect his position of intellectual property; And the estimates of Zyversa in relation to future income, expenses, capital requirements and needs for additional financing.

New factors arise from time to time, and it is not possible that Zyversa has predicted all of these factors, and Zyversa cannot evaluate the effects of such a factor on the business or the extent, in which a factor or combination of factors can significantly differentiate the actual results from those that are included in an intensive statements. This press release contained in this press release are based on information based on the date of this press release. Zyversa rejects any obligation to update such future -oriented statements in order to reflect events or circumstances according to the date of this press release, provided this is necessary in accordance with applicable law.

This press release does not represent a offer for sale or requesting a purchase offer.

Corporate, Media and IR contact:
Karen Cashmere
Chief Commercial Officer
kcashmere@zyversa.com
786-251-9641